



PATENT  
ATTORNEY DOCKET NO.: 056291-5173

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re PATENT APPLICATION of: )  
Ann-Margret LINDQVIST )  
Application No.: 10/502,355 ) Group Art Unit: 1615  
Filed: February 4, 2005 ) Examiner: Unassigned  
FOR: USE OF BENZOTHIAZEPINES HAVING )  
ACTIVITY AS INHIBITORS OF ILEAL )  
BILE ACID TRANSPORT FOR REDUCING )  
CHOLESTEROLEMIA )

Commissioner for Patents  
U.S. Patent and Trademark Office  
Customer Service Window, **Mail Stop** \_\_\_\_  
Randolph Building  
401 Dulany Street  
Alexandria, VA 22314

Date: April 12, 2005

Sir:

**INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.97(b)**

Attached is a Form PTO-1449 listing the enclosed foreign patent documents.

Attached is a Form PTO-1449 listing the enclosed foreign patent documents.

Copies of any U.S. patent documents are not enclosed.

The present Information Disclosure Statement is being filed before the mailing date of the first Office Action on the merits, and therefore no certification under 37 CFR §1.97(e) or fee under 37 CFR §1.17(p) is required.

Should a first Action on the merits have been issued on the same day as or before this IDS is filed, please accept this IDS under Rule 97(c) and charge the requisite fee to our Deposit Account under Order No. 056291-5173 and proceed to consider this IDS.

This Information Disclosure Statement is intended to be in full compliance with the rules, but should the Examiner find any part of its required content to have been omitted, prompt notice to that effect is earnestly solicited, along with additional time under Rule 97(f), to enable Applicant to fully comply.


Consideration of the foregoing and enclosures plus the return of a copy of the herewith filed Form PTO-1449 with the Examiner's initials in the left column per MPEP 609 along with an early action on the merits of this application are earnestly solicited.


**Except** for issue fees payable under 37 C.F.R. §1.18, the Director is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. §§1.16 and 1.17 which may be required, including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a **CONSTRUCTIVE PETITION FOR EXTENSION OF TIME** in accordance with 37 C.F.R. §1.136(a)(3).

Respectfully Submitted,  
**Morgan Lewis & Bockius LLP**

Date: April 12, 2005  
Morgan Lewis & Bockius LLP  
Customer No. **09629**  
1111 Pennsylvania Avenue, N.W.  
Washington, D.C. 20004  
Tel. No.: 202-739-3000  
DJB:mk

By:

  
\_\_\_\_\_  
Donald J. Bird  
Registration No. 25,323  
Tel. No.: (202) 739-5320  
Fax No.: (202) 739-3001

FORM PTO-1449 (modified) To: U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. <div style="border: 1px solid black; padding: 2px; text-align: center;">056291-5173</div>	Client Ref.
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>		
		
Date: April 12, 2005		
Applicant: Ann Margaret Lindqvist		
Appln. No.: 10/502,355		
Filing Date: February 4, 2005		
Examiner: Unassigned		Group Art Unit: 1615

U.S. PATENT DOCUMENTS						
Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
	AR	2002/142054 A1	Marlett et al.			
	BR					
	CR					
	DR					
	ER					
	FR					
	GR					

FOREIGN PATENT DOCUMENTS						English Abstract		Translation Readily Available	
		Document Number	Date MM/YYYY	Country	Inventor/Applicant Name	Enclosed	No	Enclosed	No
	HR	19825804	12/1999	DE	Frick et al.	X			
	IR	0864582 A2	09/1998	EP	Enhsen et al.				
	JR	0372542 A	06/1990	EP	Mao et al.				
	KR	2262888	07/1993	GB	Shigeo Ochi				
	LR	93/16055	08/1993	WO	Brieaddy				
	MR	94/18183	08/1994	WO	Briedday et al.				
	NR	94/18184	08/1994	WO	Brieaddy et al.				
	OR	96/05188	02/1996	WO	Brieaddy et al.				
	PR	96/08484	03/1996	WO	Lee et al.				
	QR	96/16051	05/1996	WO	Brieaddy et al.				
	RR	97/33882	09/1997	WO	Reitz et al.				
	SR	98/38182	09/1998	WO	Handlon et al.				
	TR	98/40375	09/1998	WO	Reitz et al.				
	UR	99/01149	01/1999	WO	Topping et al.				
	VR	99/32478	07/1999	WO	Li et al.				
	WR	99/35135	07/1999	WO	Handlon et al.				
	XR	99/64409	12/1999	WO	Frick et al.	X			
	YR	99/64410	12/1999	WO	Frick et al.	X			

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)									
	ZR								
	AAR								
	BBR								

Examiner	Date Considered:
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	